Bernstein Liebhard LLP has announced the filing of a shareholder class action lawsuit against Zynex, Inc. (ZYXIQ), alleging the company engaged in misrepresentations regarding revenue generation during a period spanning 2018 through 2023. According to the firm, the allegations center on an overbilling scheme that may have artificially inflated the company's reported financial performance during this multi-year period.
The litigation represents one of several securities actions the firm has undertaken recently. Concurrent class action cases have been filed against Corcept Therapeutics, addressing shareholder losses sustained between October 2024 and December 2025, and NuScale Power Corporation, targeting losses incurred between May 2025 and November 2025. These actions reflect ongoing scrutiny of corporate disclosures and accounting practices across multiple sectors.
Investors who experienced significant losses in Zynex securities are being advised to evaluate their legal options by contacting the firm's legal team. Class action lawsuits typically allow shareholders to pursue collective remedies for alleged securities violations without bearing individual litigation costs.